<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is great interest in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stem cells (TSCs) as potential therapeutic targets; however, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies targeting TSCs are limited </plain></SENT>
<SENT sid="1" pm="."><plain>A drawback is that TSC markers are often shared by <z:mpath ids='MPATH_458'>normal</z:mpath> stem cells (NSCs); thus, therapies that target these markers may cause severe injury to <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="2" pm="."><plain>To identify a potential TSC-specific marker, we focused on doublecortin-like kinase 1 (Dclk1) </plain></SENT>
<SENT sid="3" pm="."><plain>Dclk1 was reported as a candidate NSC marker in the gut, but recent reports have implicated it as a marker of differentiated cells (for example, Tuft cells) </plain></SENT>
<SENT sid="4" pm="."><plain>Using lineage-tracing experiments, we show here that Dclk1 does not mark NSCs in the intestine but instead marks TSCs that continuously produce <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> progeny in the <z:mpath ids='MPATH_491'>polyps</z:mpath> of Apc(Min/+) mice </plain></SENT>
<SENT sid="5" pm="."><plain>Specific ablation of Dclk1-positive TSCs resulted in a marked regression of <z:mpath ids='MPATH_491'>polyps</z:mpath> without apparent damage to the <z:mpath ids='MPATH_458'>normal</z:mpath> intestine </plain></SENT>
<SENT sid="6" pm="."><plain>Our data suggest the potential for developing a therapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> based on targeting Dclk1-positive TSCs </plain></SENT>
</text></document>